ClinicalTrials.gg
CompletedNCT00303381Updated Aug 6, 2013

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

A Phase 2 interventional study of Interferon-beta-1a, 44 microgram and Placebo in Ulcerative Colitis, sponsored by EMD Serono. Completed at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 243 studies in Colitis, Ulcerative with a site in Germany — 29 open to participants now, 62 under way, 26 of them phase 3. Colitis, Ulcerative · Germany.

Enrollment
99th of 202
194 · median 179
Started
2001
the only one that year
Phase 2
79 of 243
7 open now
Registered
10th of 243
by date

Among the 243 studies in Colitis, Ulcerative with a site in Germany, this one is the 99th largest by enrollment of the 202 interventional ones that give a count, is the only one that started in 2001, is one of 79 in phase 2, and was the 10th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 243 studies in Colitis, Ulcerative with a site in Germany are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Colitis, Ulcerative with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of interferon-beta-1a in subjects with active ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderately active UC, defined as:

    • Diagnosis of UC documented by clinical, radiological and endoscopic or histological findings
    • Proctosigmoidoscopic diagnosis: at least left-sided disease; the extent of the colonic inflammation is to be more than 20 centimeter from the anal verge
    • A flare in disease activity considered moderate in according to the UCSS during the 14 days before initiation of study medication. Moderate disease is defined as a UCSS between 6 and 10 with a UCSS Physician's Global Assessment less than (\<) 3 and a proctosigmoidoscopy score of 2 or 3
  • At least one previous flare-up of UC
  • Maintenance treatment with 5-aminosalicylic acid (5-ASA) at a stable dose for the management of UC is allowed, but not required. The daily dose of 5-ASA has to be stable for at least 4 weeks before Study Day 1 and has to be no more than 3.6 gram/day. This dose has to be maintained throughout the study. will not be allowed during the study, with the exceptions of inhaled steroids and topical dermatological steroids
  • Age ≥18 years, of either sex
  • Adequate bone marrow reserve: white blood cells (WBC) greater than (>) 3.5*10\^9 per liter (/L), neutrophils >1.5*10 \^9 /L, >100 *10\^9 /L, >8.5 gram per deciliter (g/dL)
  • Female subjects are to be neither pregnant nor breast-feeding and has to lack , as will be defined by either being or surgically sterile or using a hormonal , intra-uterine device, diaphragm with spermicide or not pregnant which will be established by a negative serum or urinary Human chorionic gonadotrophin (hCG) test within 7 days before Study Day 1. A pregnancy test is not required if the subject was post-menopausal or surgically sterile
  • Willingness and ability to comply with the protocol for the duration of the study
  • Written , obtained before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject can withdraw consent at any time without prejudice to his or her future medical care

Exclusion criteria

Exclusion Criteria:

  • Previous systemic treatment with interferons, therapy (for example [e.g.], cyclosporin, azathioprine, 6-mercaptopurine) or other biological treatment (e.g. anti- Cluster of differentiation [CD] 4, anti-CD5, anti- Tumour necrosis factor [TNF]-alpha, Interleukin [IL]-10) in the 3 months before Study Day 1
  • Any other drug or any experimental procedure in the 4 weeks before Study Day 1
  • More than three doses of rectally administered 5-ASA derivatives in the 2 weeks before Study Day 1
  • More than two doses of systemically or rectally administered in the 14 days before Study Day 1
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotic therapy (e.g. metronidazole) in the 2 weeks before Study Day 1
  • Use of codeine, other narcotics, loperamide or opiates after the Screening visit or during the study
  • Stool examination positive for enteric pathogens, pathogenic ova, parasites, or Clostridium toxin at Screening
  • Need for emergency surgery (uncontrollable hemorrhage, persistent non-inflammatory intestinal obstruction - at the Investigator's discretion - or perforation), elective surgery during the study, or surgery in the 4 weeks before study entry
  • Inadequate liver function, defined by a total , (AST), alanine aminotransferase (ALT) or alkaline phosphatase level >2 times the
  • Inadequate renal function, defined by serum creatinine >2.0 milligram per deciliter (mg/dL)
  • Histopathological findings of high-grade dysplasia or history of cancer (except carcinoma in situ of the cervix or adequately treated basal cell or squamous cell carcinoma of the skin)
  • Known allergies to paracetamol or to any of the ingredients of the medicinal product (that is, the active substance, human serum albumin or mannitol)
  • Severe depressive disorder or suicidal ideation, or epilepsy with a history of seizures not adequately controlled by treatment
  • Known alcohol or drug abuse within the past 5 years
  • Other serious concurrent systemic disorders incompatible with the study (at the Investigator's discretion)
  • Severe active infection (at the Investigator's discretion)
  • Dependence on a liquid diet
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Interferon-beta-1a, 44 microgram

    Drug: Interferon-beta-1a, 44 microgram

  • Experimental
    Interferon-beta-1a, 66 microgram

    Drug: Interferon-beta-1a, 66 microgram

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.

    Also known as: Rebif®

  • DrugPlacebo

    Matching Placebo will be administered subcutaneously, three times a week up to Week 8.

  • Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.

    Also known as: Rebif®

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with endoscopically confirmed remission

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

Secondary outcomes

  1. Percentage of subjects with clinical remission

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  2. Percentage of subjects with clinical remission at Week 8 and 12

    Time frame: Week 8 and 12

  3. Time to first occurrence of clinical remission

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  4. Time to first occurrence of endoscopically confirmed remission

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  5. Percentage of subjects with clinical remission two weeks after endoscopically confirmed remission

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  6. Percentage of subjects with clinical response

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  7. Time to first occurrence of clinical response

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  8. Change from Baseline in Ulcerative Colitis Scoring System (UCSS) total score and sub-scores at Week 2, 4, 6, 8 and 12

    Time frame: Baseline, Week 2, 4, 6, 8 and 12

  9. Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score and sub-scores at Week 4, 8 and 12

    Time frame: Baseline, Week 4, 8 and 12

  10. Percentage of subjects with an increase in IBDQ score of at least 15 points

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

  11. Change from Baseline in C-reactive protein level at Week 2, 4, 8 and 12

    Time frame: Baseline, Week 2, 4, 8 and 12

  12. Changes from Baseline in erythrocyte sedimentation rate at Week 2, 4, 8 and 12

    Time frame: Baseline, Week 2, 4, 8 and 12

  13. Percentage of subjects with treatment failure

    Time frame: Baseline up to Week 12 or early withdrawal or treatment failure

07

Study locations

7 sites
  • Research Site
    Munich, Germany
  • Research Site
    Ness Ziona, Israel
  • Research Site
    Den Haag, Netherlands
  • Research Site
    Singapore, Singapore
  • Research Site
    Solna, Sweden
  • Research Site
    Zug, Switzerland
  • Research Site
    Feltham, United Kingdom
08

References and documents

Publications

  • Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008 Sep 15;28(6):758-67. doi: 10.1111/j.1365-2036.2008.03778.x. PubMed 19145731 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2001, a primary completion of Jan 2003 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2006
First posted
Mar 16, 2006
Start
Dec 2001
Primary completionActual
Jan 2003
CompletionActual
Jan 2003
Last update
Aug 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00303381
Lead sponsor
EMD Serono
Collaborators
Merck Serono International SA
Responsible party
Sponsor
First posted
Mar 16, 2006
Start date
Dec 2001
Primary completion
Jan 2003
Completion
Jan 2003
Last update
Aug 6, 2013

Study contacts

Claudia Pena Rossi, M.D.
study director · Merck Serono International SA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion